-
1 Comment
Diaceutics PLC is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.
Diaceutics PLC's total revenue sank by 0.0% to $5M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $1M since the same quarter in the previous year.
Finally, its free cash flow fell by 214.2% to $-543K since the same quarter in the previous year.
Based on the above factors, Diaceutics PLC gets an overall score of 1/5.
CurrencyCode | GBP |
---|---|
ISIN | GB00BJQTGV64 |
Sector | Healthcare |
Industry | Health Information Services |
Exchange | LSE |
Market Cap | 100M |
---|---|
PE Ratio | None |
Target Price | 199.4 |
Beta | 0.79 |
Dividend Yield | None |
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. The company offers DXRX, a diagnostic commercialisation platform for precision medicine that integrates multiple pipelines of diagnostic testing data from network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and the physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DXRX.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025